Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The health economic impact of antidepressant usage from a payer's perspective: A multinational study
Autore:
Casciano, J; Doyle, J; Arikian, S; Casciano, R;
Indirizzi:
Analytica Grp, New York, NY 10016 USA Analytica Grp New York NY USA 10016Analytica Grp, New York, NY 10016 USA Columbia Univ, Sch Publ Hlth, New York, NY USA Columbia Univ New York NY USA mbia Univ, Sch Publ Hlth, New York, NY USA
Titolo Testata:
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
fascicolo: 5, volume: 55, anno: 2001,
pagine: 292 - 299
SICI:
1368-5031(200106)55:5<292:THEIOA>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
EXPENDITURE CONTROL; DEPRESSION; MARKET; DRUGS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Arikian, S Analytica Grp, 475 Pk Ave S,17th Floor, New York, NY 10016 USA Analytica Grp 475 Pk Ave S,17th Floor New York NY USA 10016 USA
Citazione:
J. Casciano et al., "The health economic impact of antidepressant usage from a payer's perspective: A multinational study", INT J CL PR, 55(5), 2001, pp. 292-299

Abstract

A multinational decision analytic model was developed to examine the treatment of major depressive disorder (MDD) in 10 European and American countries. Input to the model was obtained from a meta-analysis of current clinical trial data obtained from the published literature, and local clinical andhealth economic experts in each market. The patient- and policy-level impact of MDD treatment was measured in each of the 10 markets. The total expected cost per patient for treating MDD with venlafaxine XR during the six-month acute phase of MDD was the lowest expected cost in nine of the 10 countries studied, resulting in savings to the primary payer in almost all markets. As well as the cost savings, the higher efficacy and lower rate of dropout found for venlafaxine XR translate to a greater number of symptom-free-days (SFDs) per patient. The results of this investigation show that use ofvenlafaxine XR in most settings across Europe and the Americas will have afavourable impact on healthcare payer budgets and the overall mental health of MDD patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 20:42:31